Categories AlphaGraphs, Analysis, Finance
Preview: Square under pressure to prove worthiness as it reports Q3 earnings
Square (SQ) stock more-than-doubled in the past 52 weeks to hit an all-time high of $99.01 on September 28, before tumbling 21% to the current price of $77.76. As the company heads to its next earnings report, scheduled for Wednesday, it is under immense pressure to prove to investors that it is really worth the valuation spike.
The fintech firm earlier reported stellar results in the second quarter, when it narrowed its losses and grew adjusted revenue 60% to $385 million. The results came in above street consensus.
Gross Payment Volume (GPV) improved 30% to $21.4 billion, aided by continued contribution from large sellers (sellers that process over $125,000 a year). For the first time in the company’s history, large sellers’ contribution stood at 50% of GPV, helped by solid growth in Caviar and Cash App. A growth in large sellers will partly also be spurred by Square Register and Square for Restaurants platforms.
During the third quarter, analysts expect Square to report earnings of 11 cents per share, on a 61% improvement in the top line. The GPV is also seen to improve as analysts expect the company to attract more large sellers. An increase in the large-seller component in the total GPV is seen as a financially healthy condition for Square.
Separately, Square’s subscription and services-based revenue will likely get a boost from its recent acquisitions of Weebly and Zesty. The San Francisco, California-based company also expects its Square Solutions Partner Program, launched last quarter, to improve subscriber base in Q3.
During the prior sequential quarter, revenue from subscription and services soared 127%. During the first quarter, the growth was pegged at 98%. Market observers feel the growth rate in the third quarter will be in par with Q1 and Q2.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on